Vitruvias Therapeutics, Inc. is an experienced specialty pharmaceutical company focused on the marketing & distribution of generic prescription products within the United States and Puerto Rico.
VIATRIS
VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities. | Viatris Inc. is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. | Booth 1650 – Yupelri (COPD) Booth 1765 – Tobi Podhaler (Cystic Fibrosis) Expo 1569 – Tobi Podhaler (Cystic Fibrosis) – Informational Sessions VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions, and improving patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities. | VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions and leveraging our collective expertise to improve patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatris brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver quality medicines to patients when and where they need them.
Vertex Pharmaceuticals
Vertex invests in scientific innovation to create transformative medicines for people with serious diseases. Through cutting-edge science across multiple modalities, it has approved medicines that treat the underlying causes of multiple diseases and conditions and has a broad and deep clinical pipeline. Learn more at www.vrtx.com. | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for other serious diseases like type 1 diabetes, APOL1-mediated kidney disease and IgA nephropathy. | xxx | Vertex, a global biotechnology company, invests in scientific innovation to create transformative medicines for people with serious diseases. It has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain and continues to advance its research in these areas. Vertex has a broad and deep clinical pipeline across a range of modalities for serious kidney diseases, including APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy and autosomal dominant polycystic kidney disease.
Upsher-Smith Laboratories, Inc.
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. The company brings generics and brands to a wide array of customers, always backed by its attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.
Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com. | Teva Pharmaceutical Industries Ltd. has been developing and producing medicines to improve people’s lives for more than a century. We offer generic, biosimilars and innovative medicines with a portfolio consisting of over 3,600 products in nearly every therapeutic area. Learn more at www.tevapharm.com. ©2023 Teva Neuroscience, Inc. NPS-40586 May 2023
Takeda Pharmaceuticals U.S.A., Inc.
As one of the world’s leading biopharmaceutical companies, Takeda is committed to bringing Better Health and a Brighter future to people worldwide. We aspire to bring our leadership in translating science into life-changing medicines to the next level, in our core focus areas; oncology, gastroenterology, neuroscience, rare diseases, plasma-derived therapies, and vaccines.
Shionogi
Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., an over 145-year-old global pharmaceutical company with headquarters in Osaka, Japan. In the U.S., Shionogi Inc. leverages our science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in our core areas of infectious diseases and pain, as well as other areas of high medical need. Shionogi strives constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve. | Shionogi, Inc. is a subsidiary of Shionogi & Co., Ltd., a 145-year-old global pharmaceutical company headquartered in Osaka, Japan. Shionogi Inc. leverages our science-based heritage to develop & commercialize pharmaceutical products to treat unmet medical needs in our core area of infectious diseases and other areas of high medical need. | Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a Japanese research-driven pharmaceutical company. Since 1878, we have been harnessing the full potential of science to address global health challenges. Over the past six decades, we have discovered several novel antibiotics and medications for HIV and influenza. Today, we’re building on our scientific legacy by providing an antibiotic for difficult-to-treat Gram-negative bacterial infections and developing an investigational oral antiviral for COVID-19. Beyond infectious